Chronic Lymphoproliferative Diseases (CLPD)NCT05032313
Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer
An observational study of Chronic Lymphoproliferative Diseases (CLPD), run by Becton, Dickinson and Company at 6 sites in 5 countries.
Trial summary
Multi-site, prospective performance study to determine equivalency between the investigational CLPD Limited Panel on the FACSLyric system versus the final clinical diagnosis. Read more about this study
- Who is it for?
- Ages 22 years and older
- Conditions the study is for
- Chronic Lymphoproliferative Diseases (CLPD)
- What is being tested?
- IUO CLPD Limited Panel
- How many people
- 371 participants
- Where
- 6 sitesin 5 countries
- Study dates
- 26 Apr 2021to 29 Dec 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: A minimum of evaluable 250 remnant/leftover peripheral blood, bone marrow, and lymph node specimens from routine flow cytometry laboratory testing for hematological disorders. Specimens from healthy subjects will be excluded. Specimens are from subjects irrespective of race, gender, and ethnicity. Specimen from subject >22 years of age .
Who may be able to join
- Specimen collected/handled prior to enrollment in accordance with site policies and procedures.
- Specimen with adequate volume (approximately 300 µL) to complete protocol tests.
- Specimen is leftover PB, BM, or LN from routine flow cytometry laboratory testing for chronic lymphoproliferative disorders, other hematological disorders, non-hematological tumors (e.g., solid tumors), or other non-hematological disorders (non-malignant).
- Specimen from newly diagnosed or relapsed subject.
- Only one type of specimen, either PB, BM, or LN shall be enrolled per given subject.
- Specimen is stored at room temperature, upon receipt by the site.
Show all 10Show fewer
- PB and BM specimens are collected in EDTA (K2 or K3) or heparin (sodium or lithium).
- LN specimens collected in PBS, culture media (e.g., RPMI-1640), saline, or saline wrapped gauze at the discretion of the Investigator.
- Age of specimen for PB and BM (time of collection to start of first pre-wash): ≤ 24 hours. (Note: No Age of specimen claim is being made for LN)
- Specimens are from subjects irrespective of race, gender, and ethnicity.
Who cannot join
- Specimen is from healthy subject.
- Specimen is from subject undergoing any treatment for any form of L\&L.
- Specimen from subject <22 years of age.
- Specimen is from subject with minimal residual disease (MRD) as determined by the site.
- Specimen is from subject suspected of acute leukemia (e.g., T-ALL, BCP-ALL, AML) or myeloid dysplastic syndrome (MDS).
- Visibly clotted specimen.
Show all 10Show fewer
- Visibly hemolyzed specimen.
- Frozen specimen.
- Refrigerated specimen.
- Fixed specimen.
Trial locations and contacts
6 sites in 5 countries.
6 sites in 5 countries
United States2 sites
University of North Carolina
Chapel Hill, North Carolina, 27514
Corepath Laboratories
San Antonio, Texas, 78229
About this study
Official title: Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel (BD OneFlow™ LST and OneFlow™ B-CLPD T1) on the BD FACSLyric™ Flow Cytometer Using Leftover, De-identified Specimens
Multi-site, prospective performance study to determine equivalency between the investigational CLPD Limited Panel on the FACSLyric system versus the final clinical diagnosis.
Read the detailed description
Hematology laboratories rely on flow cytometry technology (in addition to classic hematological methods) to aid in screening, diagnosing, and monitoring patients with hematological disorders. High speed and broad applicability of flow cytometry allows for the diagnosis. Currently, there are no consensus panels being used; consequently, the leukemia \& lymphoma (L\&L) testing remains a single-vial antibody being used with various in-house laboratory developed tests (LDTs) being used to test patient specimens. Furthermore, the analysis of flow cytometer generated data is not standardized and requires a high level of expertise and training for interpretation of complex data. Therefore, optimized and standardized immunostaining protocols for the diagnosis, classification, and prognostic sub-classification of hematological malignancies are needed.
This investigational reagent panel for chronic lymphoproliferative diseases (CLPD) is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations on the BD FACSLyric flow cytometer . These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell CLPD, T-cell CLPD, and NK-cell CLPD.
Enrollment will occur at up to 8 investigational sites . Data will be acquired from Eligible remnant/leftover specimens on the BD FACSLyric flow cytometer and evaluated by site personnel and expert analysts .
The final diagnosis and the affected cell population will be determined by site standard of care .
Analysis of data will evaluate identification of normal vs abnormal cell population of the expert \& site analysts as compared to the final diagnosis.
- Being tested
- IUO CLPD Limited Panel
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IUO CLPD Limited PanelDiagnostic test
This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease .
| Study group | Role | What they receive |
|---|---|---|
| Remnant/ Leftover specimens | Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for hematological disorders. Receives: Diagnostic Test: IUO CLPD Limited Panel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison between expert analysts' determination of normal and abnormal specimen and final diagnosis
Determine equivalence between the investigational OneFlow CLPD Limited Panel on FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal (T-cell, B-cell, and NK-cell) or Abnormal (T-cell or B-cell or NK-cell) phenotype using leftover, hematologically abnormal specimens .
Sensitivity and specificity are calculated
Measured: Age of specimen for PB and BM (time of collection to start of first pre-wash): ≤ 24 hours.
Secondary outcomes (1)
Comparison between expert analysts' determination of normal and abnormal Peripheral Blood (PB) specimen and final diagnosis
Determine equivalence between the investigational OneFlow CLPD Limited Panel on FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal or Abnormal phenotype using leftover, hematologically abnormal peripheral blood (PB) specimens.
Sensitivity and specificity are calculated .
Measured: Age of specimen for PB (time of collection to start of first pre-wash): ≤ 24 hours.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2021
- Study start26 Apr 2021
- Primary completion29 Dec 2023
- Study completion29 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Lymphoproliferative Diseases (CLPD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 371 participants (actual)
Sponsor and investigators
- Lead sponsor
- Becton, Dickinson and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Imelda Omana-Zapata, MD, PHD, Study director, Becton, Dickinson and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05032313
- Sponsor's protocol ID
- CAS-OFLYRICLB-IVDR
- Status last verified
- Feb 2024
- First submitted
- 27 Aug 2021
- Last updated
- 28 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel (BD OneFlow™ LST and OneFlow™ B-CLPD T1) on the BD FACSLyric™ Flow Cytometer Using Leftover, De-identified Specimens
- ClinicalTrials.gov ID
- NCT05032313
- Acronym / sponsor ID
- CAS-OFLYRICLB-IVDR
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 371 participants (actual)
- Lead sponsor
- Becton, Dickinson and CompanyIndustry (pharma, biotech, devices)
- Study start
- 26 Apr 2021 (actual)
- Primary completion
- 29 Dec 2023 (actual)
- Study completion
- 29 Dec 2023 (actual)
- First posted
- 2 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multi-site, prospective performance study to determine equivalency between the investigational CLPD Limited Panel on the FACSLyric system versus the final clinical diagnosis.
Detailed description
Hematology laboratories rely on flow cytometry technology (in addition to classic hematological methods) to aid in screening, diagnosing, and monitoring patients with hematological disorders. High speed and broad applicability of flow cytometry allows for the diagnosis. Currently, there are no consensus panels being used; consequently, the leukemia \& lymphoma (L\&L) testing remains a single-vial antibody being used with various in-house laboratory developed tests (LDTs) being used to test patient specimens. Furthermore, the analysis of flow cytometer generated data is not standardized and requires a high level of expertise and training for interpretation of complex data. Therefore, optimized and standardized immunostaining protocols for the diagnosis, classification, and prognostic sub-classification of hematological malignancies are needed.
This investigational reagent panel for chronic lymphoproliferative diseases (CLPD) is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations on the BD FACSLyric flow cytometer . These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having, or suspected of having, B-cell CLPD, T-cell CLPD, and NK-cell CLPD.
Enrollment will occur at up to 8 investigational sites . Data will be acquired from Eligible remnant/leftover specimens on the BD FACSLyric flow cytometer and evaluated by site personnel and expert analysts .
The final diagnosis and the affected cell population will be determined by site standard of care .
Analysis of data will evaluate identification of normal vs abnormal cell population of the expert \& site analysts as compared to the final diagnosis.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Remnant/ Leftover specimens | – | Diagnostic Test: IUO CLPD Limited PanelSpecimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for hematological disorders. |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- A minimum of evaluable 250 remnant/leftover peripheral blood, bone marrow, and lymph node specimens from routine flow cytometry laboratory testing for hematological disorders. Specimens from healthy subjects will be excluded. Specimens are from subjects irrespective of race, gender, and ethnicity. Specimen from subject >22 years of age .
Key inclusion criteria (10 listed)
- Specimen collected/handled prior to enrollment in accordance with site policies and procedures.
- Specimen with adequate volume (approximately 300 µL) to complete protocol tests.
- Specimen is leftover PB, BM, or LN from routine flow cytometry laboratory testing for chronic lymphoproliferative disorders, other hematological disorders, non-hematological tumors (e.g., solid tumors), or other non-hematological disorders (non-malignant).
- Specimen from newly diagnosed or relapsed subject.
- Only one type of specimen, either PB, BM, or LN shall be enrolled per given subject.
Key exclusion criteria (10 listed)
- Specimen is from healthy subject.
- Specimen is from subject undergoing any treatment for any form of L\&L.
- Specimen from subject <22 years of age.
- Specimen is from subject with minimal residual disease (MRD) as determined by the site.
- Specimen is from subject suspected of acute leukemia (e.g., T-ALL, BCP-ALL, AML) or myeloid dysplastic syndrome (MDS).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IUO CLPD Limited PanelThis Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease . | Diagnostic test | Remnant/ Leftover specimens |
Primary outcome
Comparison between expert analysts' determination of normal and abnormal specimen and final diagnosis
Time frame: Age of specimen for PB and BM (time of collection to start of first pre-wash): ≤ 24 hours.
Determine equivalence between the investigational OneFlow CLPD Limited Panel on FACSLyric system results analyzed by two independent experts versus the final clinical diagnosis for Normal (T-cell, B-cell, and NK-cell) or Abnormal (T-cell or B-cell or NK-cell) phenotype using leftover, hematologically abnormal specimens . Sensitivity and specificity are calculated
1 secondary outcome
Comparison between expert analysts' determination of normal and abnormal Peripheral Blood (PB) specimen and final diagnosis
Time frame: Age of specimen for PB (time of collection to start of first pre-wash): ≤ 24 hours.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Feb 2024.
- Individual participant dataSharing planned: No
Related trials for Chronic Lymphoproliferative Diseases (CLPD)
Not yet recruitingObservational study
Cell Population Data in CLPD and Viral Disease
Chronic Lymphoproliferative Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Imelda Omana-Zapata, MD, PHD study director
Becton, Dickinson and Company
6 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Lymphoproliferative Diseases (CLPD), run by Becton, Dickinson and Company at 6 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States, Portugal, Spain, Switzerland, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison between expert analysts' determination of normal and abnormal specimen and final diagnosis (time frame: Age of specimen for PB and BM (time of collection to start of first pre-wash): ≤ 24 hours.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2024.